ArticleBriefings in bioinformatics2025
DSCC: disease subtyping using spectral clustering and community detection from consensus networks.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy.MedComm · 2026Review
- Article
- CSIE: cancer subtyping via inference and ensemble.Briefings in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Molecular subtyping is fundamental in cancer research and clinical management of cancer, guiding treatment planning, monitoring therapeutic response, and informing prognosis. Early methods were designed specifically for gene expression data due to the lack of other molecular data types. Thanks to breakthroughs in high-throughput technologies, recent subtyping tools have shifted their focus to integrating multi-omics profiles to uncover novel subtypes that better reflect genetic variation, molecular pathogenesis, tumor heterogeneity, and host response biological mechanisms. However, these integrative approaches have not been able to fully exploit the complementary potentials of diverse molecular data types. They often rely on specific omics types with large common sample size and fail to incorporate important biological knowledge in their models. Here, we introduce Disease subtyping using Spectral clustering and Community detection from Consensus networks (DSCC), a method designed to identify meaningful disease subtypes from a wide range of molecular data, including gene expression, miRNA expression, DNA methylation, copy number variation, somatic mutations, protein abundance, and metabolite levels. We demonstrate the superiority of DSCC over state-of-the-art cancer subtyping methods using 43 cancer datasets with more than 11,000 patients. Furthermore, the incorporation of DSCC-derived subtype information as a covariate in prognostic models improves survival prediction accuracy and robustness. The DSCC source code, data, and scripts for reproducing all results in this study are available at https://github.com/tinnlab/DSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.